Organic compounds
AssigneeIntra-Cellular Therapies, Inc.
InventorsLawrence P. WENNOGLE, Robert DAVIS, Peng LI
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds having a capacity for PDE1 inhibition which may be used as tracers for use in diagnostic techniques, biomarkers for phosphodiesterase 1 (PDE1) in vivo, methods for treating and/or developing novel therapies for PDE1-associated conditions, and to methods of detection and treatment.
Claims46
(canceled)
(canceled)
A compound according to Formula II:
- wherein
- R1, R2 and R5 are independently selected from optionally T-substituted C1-4alkyl, H or T (tritium, 3H);
- R3, R4, R11, R12, R14 and R15 are independently selected from H or T;
- R6, R7, R8, R9 and R10 are independently selected from halogen (e.g., F), H or T;
- R13 is C1-4alkyl, methylcarbonyl, hydroxyethyl, carboxylic acid, sulfonamide, (optionally halo- or hydroxy-substituted) phenyl, (optionally halo- or hydroxy-substituted) pyridyl, thiadiazolyl, or optionally C1-4alkyl substituted pyrrolidyl, any of which is optionally substituted at one or more positions with tritium (T) in place of H;
- wherein at least one position on the compound is substituted with tritium (T) in place of H,
- in free, pharmaceutically acceptable salt or prodrug form, including its enantiomers, diastereoisomers and racemates.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.